electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The company was founded in 2005 and is based in Basking Ridge, New Jersey.
BASKING RIDGE, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will be available at Little Grapevine™ (www.littlegrapevine.com) beginning today, May 29, 2020, at 10:30 a.m. Eastern Standard Time. Accompanying the presentation will be a short executive introduction, as well as a brief Q&A with Mr. Goldberger. No fee is required to join or view the company’s Little Grapevine Conference presentation, as it is open to the public.
Investment Thesis electroCore share price performance since IPO. Source: TradingView. electroCore (NASDAQ:ECOR) has been a crushing disappointment for its investors since its June 2018 IPO. Despite the promise of its FDA approved, non-invasive treatment for migraines - gammaCore - cleared for the acute and preventive treatment of migraines and episodic...
BASKING RIDGE, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced first quarter 2020 financial results and provided an operational update. Received 510(k) clearance from FDA to expand the gammaCore label into migraine prevention. Announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore (nVNS) in the treatment of cluster headache in adults, through September 2020.